Distinct mechanistic pathways of early tauopathy revealed by MAPT mutations
Authors:
Preprint
Abstract
Tau pathology underlies a broad spectrum of neurodegenerative disorders, collectively termed tauopathies, yet these diseases exhibit striking heterogeneity in their biological mechanisms and clinical outcomes. The basis for this heterogeneity remains poorly understood. Here, we address this question using knock-in mouse models expressing two distinct frontotemporal dementia-associated tau mutations to define how different tau variants drive divergent pathogenic programs in vivo . We find that the two mutations give rise to fundamentally different trajectories of tau pathogenesis. One trajectory is marked by progressive tau hyperphosphorylation and cytoskeletal destabilization occurring in the absence of detectable tau seed formation. In contrast, an alternative trajectory is characterized by tau hypophosphorylation, early seed formation, and alterations in nucleotide metabolism and chromatin organization, without overt cytoskeletal disruption. With aging, tau in this latter pathway transitions to a hyperphosphorylated state and forms mature fibrillar aggregates. Genetic enhancement of β-amyloid selectively accelerates fibril formation, particularly in the model exhibiting early seeding. Together, these findings demonstrate that distinct tau mutations can engage separable pathogenic mechanisms, providing a biological framework for the heterogeneity observed across tauopathies, and highlighting the need for mechanism-informed therapeutic strategies and patient stratification. Abstract Figure: Graphical Schematic representation comparing two trajectories of tau pathology. The S305N mutation promotes a 4R isoform shift, cytoskeletal damage and synapse loss, and accumulation of soluble hyperphosphorylated tau. Tau remains soluble even at old ages. In contrast, the P301S mutation generates hypophosphorylated, seed-competent tau that forms fibrils. The effect of amyloid is slow in the S305N, but results in accelerated acceleration of pathology in the P301S. Figure made with Biorender.com .Keywords
All Related Versions
This publication has 73 references indexed in Scilit:
- Human MAPT knockin mouse models of frontotemporal dementia for the neurodegenerative research communityCell Reports Methods, 2025
- MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathologyAnnals of Clinical and Translational Neurology, 2021
- Integrated analysis of multimodal single-cell dataCell, 2021
- Single-Nucleus RNA-Seq Is Not Suitable for Detection of Microglial Activation Genes in HumansCell Reports, 2020
- Comprehensive Integration of Single-Cell DataCell, 2019
- Phosphorylation of serine 305 in tau inhibits aggregationNeuroscience Letters, 2019
- Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental ChangesMolecular Cell, 2016
- Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse ModelNeuron, 2007
- Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau TransgenesNeurobiology of Disease, 2000
- Phosphorylation of Tau at Both Thr 231 and Ser 262 Is Required for Maximal Inhibition of Its Binding to MicrotubulesArchives of Biochemistry and Biophysics, 1998